Killer Bees Market Brief April 02, 2026

The Sting

Oracle fired 30,000 people on Tuesday. The stock went up 5%. On the same day, SpaceX filed for the largest IPO in human history, and the FDA approved a weight-loss pill that could reshape a $150 billion market. One company is destroying jobs to fund machines. Another is going public at a valuation larger than all but five S&P 500 companies. The third just made obesity treatment as simple as a morning multivitamin. Three stories, one theme: the price of admission to the future just got very specific.

Oracle: $6 Billion in Profit. 30,000 Pink Slips.

Oracle sent a five-line email at 6 a.m. on Tuesday no warning, no HR call, no manager conversation telling up to 30,000 employees their roles had been eliminated. Access to company systems was cut within hours. Workers in the U.S., India, Canada, and Mexico all got the same message from the same faceless sender: "Oracle Leadership."

Here's what most coverage glossed over: Oracle just reported an exceptional quarter. Revenue up 22%. EPS of $1.79, crushing the $1.55 estimate. The contracted backlog swelled past $523 billion. This isn't a company in crisis. This is a company that looked at record earnings and decided the humans who generated them were the line item to cut.

The math is the quiet part said loud. TD Cowen estimated that axing 30,000 heads frees up $8–10 billion in cash flow , cash Oracle desperately needs because its AI data center buildout has turned free cash flow to minus $10 billion. The company took on $58 billion in new debt in two months. Multiple banks have pulled back from financing its projects. ORCL is down 57% from its September high of $345.72 — yet 31 of 41 analysts still rate it "Strong Buy" with a $265 target. The message from the market is brutally clear: the humans were the problem, not the strategy. Whether that logic survives actually converting a $523 billion backlog with 18% fewer people is the question nobody's stress-testing.

SpaceX Files for Liftoff: $1.75 Trillion Into a War

Same day Oracle was emailing people into unemployment, SpaceX submitted a confidential IPO registration. Target valuation: above $1.75 trillion. Potential raise: $75 billion more than 3x Alibaba's record. Twenty-one banks on the deal, internally codenamed "Project Apex." If it prices there, SpaceX would be larger than every S&P 500 company except five. On Day One.

The timing is what's fascinating. SpaceX is filing during a hot war with Iran, Brent whipsawing between $100 and $109 in 48 hours, VIX at 31, and the Nasdaq coming off its steepest weekly drop in nearly a year. Bloomberg puts it on track for June first of a potential mega-IPO trio ahead of OpenAI and Anthropic. The retail kicker: SpaceX is reportedly offering a 30% retail allocation, triple the Wall Street norm. In a market starved for new issuance, they're betting Main Street wants in badly enough to buy through the turbulence.

The bull case writes itself, Starlink near $20 billion in revenue, 9+ million subs, xAI bolted on. The bear case is simpler than people think: even great companies flop in hostile markets, and June is a long way from here.

Chart of the Week: The Oracle Paradox

ORCL stock vs. revenue growth since September 2025

Oracle peaked at $345.72 last September. It's since shed 57% — the worst drawdown among major enterprise tech. In that same window: revenue +22%, EPS beat by 15%, backlog past $523 billion. The stock and the fundamentals are running in opposite directions at full speed.

The market isn't pricing Oracle's current business. It's pricing the risk of the transition — $58 billion in new debt, negative FCF, and capex that makes even AI bulls nervous. The 30,000 layoffs are Oracle admitting the old company and the new one can't coexist. Whether the new one is worth $265 depends entirely on AI infra demand staying white-hot — or whether Oracle just loaded up on debt to build into a cooling cycle.

The Hive Mind

FinTwit can't stop talking about the SpaceX retail allocation — r/wallstreetbets already has "day one" strategy threads. Meanwhile, Lilly's Foundayo stole pharma Twitter: LLY popped 4.7% to $961 on the FDA approval, but it's the $149/month price tag getting more play than the clinical data. The vibe is "finally, a GLP-1 I don't have to inject." Lilly also quietly dropped a $7.8 billion Centessa acquisition the same day nobody's talking about it, which probably means they should be.

The Thread

Oracle gutted 18% of its workforce to fund AI infrastructure it can't yet monetize. SpaceX filed for the largest IPO ever into a market that can't decide if it's risk-on or risk-off. Lilly got FDA approval for a pill that could democratize a $150 billion market but only if payers cover it. Each is making a massive bet that the future looks nothing like the present. The question isn't whether they're right. It's what happens when all three bets need to pay off at the same time and the Strait of Hormuz is still closed.